AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39571342 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (200 mL daily, ∼600 mg nitrate)
Number of subjects: 31
Study 39571342 — intervention group
Group type: COMPARATOR
Intervention: Placebo (∼60 mg nitrate)
Number of subjects: 31
Study 39571543 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GHT)
Number of subjects: 207
Study 39571597 — intervention group
Group type: EXPERIMENTAL
Intervention: High certainty of survival benefit
Number of subjects: 870
Study 39571597 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year delay in FDA approval time
Number of subjects: 870
Study 39571597 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low certainty of survival benefit
Number of subjects: 870
Study 39571597 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect on surrogate endpoint
Number of subjects: 870
Study 39571596 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course hypofractionated proton beam therapy
Number of subjects: 39
Study 39571744 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (AboBoNT-A) injections
Number of subjects: 384
Study 39571744 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (AboBoNT-A) injections with guidance technique
Number of subjects: 384
Study 39572166 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation and conventional medical management
Number of subjects: 36
Study 39572166 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management alone
Number of subjects: 36
Study 39572264 — intervention group
Group type: EXPERIMENTAL
Intervention: CD25+FoxP3+ cell rate
Number of subjects: 0
Study 39572264 — intervention group
Group type: EXPERIMENTAL
Intervention: CK+CD86+ cell rate
Number of subjects: 0
Study 39572264 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+CD38+ MFI
Number of subjects: 0
Study 39572264 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8β infiltration
Number of subjects: 0
Study 39572264 — intervention group
Group type: EXPERIMENTAL
Intervention: CK+HLAabc+ cell rate
Number of subjects: 0
Study 39572264 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+CD28+ MFI
Number of subjects: 0
Study 39572264 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CD8+CD38+ MFI
Number of subjects: 0
Study 39572264 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CD8+CD28+ MFI
Number of subjects: 0
Study 39572271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% intraperitoneally during and after surgery
Number of subjects: 225
Study 39572271 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (placebo) intraperitoneally during and after surgery
Number of subjects: 225
Study 39572389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CRMRF and PNF treatment
Number of subjects: 62
Study 39572389 — intervention group
Group type: COMPARATOR
Intervention: PNF alone
Number of subjects: 62
Study 39572395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg once daily) in combination with bendamustine and rituximab (IBR) for six 28-day cycles
Number of subjects: 56
Study 39572487 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up® (FCU®)
Number of subjects: 206
Study 39572487 — intervention group
Group type: COMPARATOR
Intervention: Community comparison arm
Number of subjects: 206
Study 39572525 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant oncolytic virus orienX010 and anti-PD-1 toripalimab for 12 weeks before surgery
Number of subjects: 30
Study 39572681 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=25)
Number of subjects: 50
Study 39572681 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis patients (n=25)
Number of subjects: 50
Study 39572739 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) group, 250 µg injected into the silicone oil after surgery and at weeks 3 and 6 postoperatively.
Number of subjects: 74
Study 39572739 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 74
Study 39572763 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (SG or RYGB)
Number of subjects: 54
Study 39572763 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (SG)
Number of subjects: 54
Study 39572763 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (RYGB)
Number of subjects: 54
Study 39572763 — intervention group
Group type: COMPARATOR
Intervention: Dietary Restriction (Control)
Number of subjects: 54
Study 39572762 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Universal Principles for Real-world Observational Studies (AUPROS)
Number of subjects: 0
Study 39572762 — intervention group
Group type: EXPERIMENTAL
Intervention: AUPROS
Number of subjects: 0
Study 39572897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-supervision group (TG)
Number of subjects: 40
Study 39572897 — intervention group
Group type: COMPARATOR
Intervention: Direct supervision group (DG)
Number of subjects: 40
Study 39572979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 300 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks until disease progression or unacceptable toxicity
Number of subjects: 15
Study 39572979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 300 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks
Number of subjects: 15
Study 39574036 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESP)
Number of subjects: 105
Study 39574036 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPV)
Number of subjects: 105
Study 39574036 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard general anaesthesia without intervention)
Number of subjects: 105
Study 39574082 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (not specified in detail)
Number of subjects: 4153
Study 39574082 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid anxiety symptoms
Number of subjects: 4153
Study 39574082 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness
Number of subjects: 4153
Study 39574082 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for informal care
Number of subjects: 4153
Study 39574082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cognitive capacity
Number of subjects: 4153
Study 39574082 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of chronic pain
Number of subjects: 4153
Study 39574082 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe depressive symptoms
Number of subjects: 4153
Study 39574099 — intervention group
Group type: EXPERIMENTAL
Intervention: Daycare attendance
Number of subjects: 178
Study 39574099 — intervention group
Group type: EXPERIMENTAL
Intervention: Later birth order
Number of subjects: 178
Study 39574099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibship size, delivery methods, and breastfeeding duration
Number of subjects: 178
Study 39574115 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic profiling using next generation sequencing with a pan-cancer comprehensive panel.
Number of subjects: 0
Study 39574115 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic profiling results discussed at multidisciplinary tumor boards.
Number of subjects: 0
Study 39574115 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients participating in clinical trials post-genomic profiling.
Number of subjects: 0
Study 39574155 — intervention group
Group type: EXPERIMENTAL
Intervention: Elamipretide
Number of subjects: 74
Study 39574155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 39574158 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekday lunchtime meals delivered by a local volunteer or driver who also provides socialization and wellness checks
Number of subjects: 2300
Study 39574158 — intervention group
Group type: COMPARATOR
Intervention: Biweekly delivery of 10 frozen meals to participants' homes
Number of subjects: 2300
Study 39574186 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine maleate (oral, three times daily for 24 hours)
Number of subjects: 0
Study 39574186 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral, three times daily for 24 hours)
Number of subjects: 0
Study 39574193 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured multimodal lifestyle program (including diet, exercise, cognitive training, vascular/metabolic risk management, social stimulation, sleep/stress management) supported by the LETHE App.
Number of subjects: 156
Study 39574193 — intervention group
Group type: COMPARATOR
Intervention: Self-guided program (regular health advice; simplified App with no personalized/interactive content).
Number of subjects: 156
Study 39574193 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured multimodal lifestyle program.
Number of subjects: 156
Study 39574193 — intervention group
Group type: COMPARATOR
Intervention: Self-guided program.
Number of subjects: 156
Study 39574198 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthogeriatric co-management
Number of subjects: 2071
Study 39574198 — intervention group
Group type: COMPARATOR
Intervention: Usual orthopedic care (control)
Number of subjects: 2071
Study 39574220 — intervention group
Group type: EXPERIMENTAL
Intervention: MBX 2109 (200, 400, 600, and 900 μg)
Number of subjects: 40
Study 39574220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 39574220 — intervention group
Group type: EXPERIMENTAL
Intervention: MBX 2109
Number of subjects: 40
Study 39574348 — intervention group
Group type: EXPERIMENTAL
Intervention: Brensocatib (single oral dose)
Number of subjects: 28
Study 39574505 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 0
Study 39574505 — intervention group
Group type: COMPARATOR
Intervention: HC group
Number of subjects: 0
Study 39574508 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 10% administered at various dosing regimens (0.4-2 g/kg once every 1-4 weeks)
Number of subjects: 44
Study 39574508 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 10% with dose splitting over multiple days
Number of subjects: 44
Study 39574508 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 10% with dosing intervals more frequent than Q4W
Number of subjects: 44
Study 39574508 — intervention group
Group type: COMPARATOR
Intervention: IVIG 10%
Number of subjects: 44
Study 39574523 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 13
Study 39574523 — intervention group
Group type: COMPARATOR
Intervention: Low-fat isoenergetic control diet
Number of subjects: 13
Study 39574950 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT-A
Number of subjects: 940
Study 39574950 — intervention group
Group type: COMPARATOR
Intervention: IVF-ET
Number of subjects: 940
Study 39575028 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-PD-L1 (Durvalumab) and anti-CTLA-4 (Tremelimumab) for three cycles of four weeks/cycle along with external beam radiation for five weeks, followed by wide surgical resection and adjuvant Durvalumab monotherapy for four cycles.
Number of subjects: 18
Study 39575028 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-PD-L1 (Durvalumab) and anti-CTLA-4 (Tremelimumab) with radiation.
Number of subjects: 18
Study 39575188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg once daily along with 1 g of mesalamine three times daily
Number of subjects: 70
Study 39575188 — intervention group
Group type: COMPARATOR
Intervention: Placebo along with 1 g of mesalamine three times daily
Number of subjects: 70
Study 39575565 — intervention group
Group type: EXPERIMENTAL
Intervention: EMB-09 (a novel Fc-silenced tetravalent PD-L1/OX40 bispecific antibody)
Number of subjects: 0
Study 39575565 — intervention group
Group type: EXPERIMENTAL
Intervention: EMB-09
Number of subjects: 0
Study 39575611 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine therapy
Number of subjects: 0
Study 39575611 — intervention group
Group type: COMPARATOR
Intervention: Morphine therapy
Number of subjects: 0
Study 39575620 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 135
Study 39575620 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 135
Study 39575620 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (subset with higher-than-median baseline anxiety)
Number of subjects: 135
Study 39575620 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS (subset with higher-than-median baseline anxiety)
Number of subjects: 135
Study 39575727 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking THC-predominant cannabis (S-THC)
Number of subjects: 22
Study 39575727 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporizing THC-predominant cannabis (V-THC)
Number of subjects: 22
Study 39575727 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporizing cannabidiol-predominant cannabis (V-CBD)
Number of subjects: 22
Study 39575728 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfers (UCT) + Medium-Quantity Lipid-Based Nutrient Supplement (LNS)
Number of subjects: 0
Study 39575728 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfers (UCT) + Medium-Quantity Lipid-Based Nutrient Supplement (LNS) + Social and Behaviour Change Communication (SBCC)
Number of subjects: 0
Study 39575728 — intervention group
Group type: COMPARATOR
Intervention: Unconditional Cash Transfers (UCT)
Number of subjects: 0
Study 39575760 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 200
Study 39575760 — intervention group
Group type: COMPARATOR
Intervention: Moderate hyperglycemia
Number of subjects: 200
Study 39575760 — intervention group
Group type: COMPARATOR
Intervention: Severe hyperglycemia
Number of subjects: 200
Study 39575760 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 200
Study 39575854 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma pTau217 ratio (pTau217R)
Number of subjects: 144
Study 39575943 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture fixation
Number of subjects: 88
Study 39575943 — intervention group
Group type: COMPARATOR
Intervention: Tension band wiring (control)
Number of subjects: 88
Study 39575944 — intervention group
Group type: EXPERIMENTAL
Intervention: nPAP therapy (BiPAP, APAP, CPAP, ASV)
Number of subjects: 241
Study 39575944 — intervention group
Group type: EXPERIMENTAL
Intervention: nPAP therapy
Number of subjects: 241
Study 39576059 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port transoral robotic surgery (SP TORS) for tongue base resection (TBR)
Number of subjects: 25
Study 39576120 — intervention group
Group type: EXPERIMENTAL
Intervention: BD Onclarity HPV assay
Number of subjects: 3129
Study 39576120 — intervention group
Group type: COMPARATOR
Intervention: Screening HPV-DNA assay (Cobas 4800 or HC2)
Number of subjects: 3129
Study 39576120 — intervention group
Group type: COMPARATOR
Intervention: Cytology, p16/ki67 and E6/E7 mRNA triage results
Number of subjects: 3129
Study 39576191 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 70
Study 39576191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 39576286 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCT (robot-assisted exoskeleton gait training)
Number of subjects: 14
Study 39576286 — intervention group
Group type: COMPARATOR
Intervention: CT (conventional therapy)
Number of subjects: 14
Study 39576286 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCT
Number of subjects: 14
Study 39576286 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 14
Study 39576432 — intervention group
Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa Q1W
Number of subjects: 0
Study 39576432 — intervention group
Group type: COMPARATOR
Intervention: Emicizumab Q1W or every 2 weeks
Number of subjects: 0
Study 39576433 — intervention group
Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa
Number of subjects: 0
Study 39576637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinics with nurse care management for OUD treatment
Number of subjects: 290071
Study 39576637 — intervention group
Group type: COMPARATOR
Intervention: Usual care clinics
Number of subjects: 290071
Study 39576675 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS and/or email reminders
Number of subjects: 446
Study 39576675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 446
Study 39576675 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall vaccination coverage
Number of subjects: 446
Study 39576675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination coverage before and after COVID-19 pandemic
Number of subjects: 446
Study 39576675 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥65 years
Number of subjects: 446
Study 39576675 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous influenza vaccination
Number of subjects: 446
Study 39576683 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based self-management intervention (AEGORA)
Number of subjects: 122
Study 39576683 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 122
Study 39576761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy plus stenting
Number of subjects: 417
Study 39576761 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thrombectomy alone
Number of subjects: 417
Study 39576798 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (intensive dietary education, food reformulation, environmental changes to facilitate salt reduction, and salt meter utilization)
Number of subjects: 219
Study 39576798 — intervention group
Group type: COMPARATOR
Intervention: Standard education only (control group)
Number of subjects: 219
Study 39576946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent FOLFIRI plus PAN (arm A)
Number of subjects: 137
Study 39576946 — intervention group
Group type: COMPARATOR
Intervention: Continuous FOLFIRI plus PAN (arm B)
Number of subjects: 137
Study 39576962 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib 200 mg daily from day -3 through +100 or +180, followed by a taper
Number of subjects: 42
Study 39576962 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib 200 mg daily
Number of subjects: 42
Study 39576962 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib combined with standard GvHD prophylaxis
Number of subjects: 42
Study 39576965 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction
Number of subjects: 39
Study 39576965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance for MRD-negative patients (n=24, group A)
Number of subjects: 39
Study 39576965 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCT for MRD-positive transplant-eligible patients (n=8, group B)
Number of subjects: 39
Study 39576965 — intervention group
Group type: EXPERIMENTAL
Intervention: KRd consolidation for MRD-positive transplant-ineligible patients (n=4, group C)
Number of subjects: 39
Study 39576965 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study results
Number of subjects: 39
Study 39576977 — intervention group
Group type: EXPERIMENTAL
Intervention: Length AI algorithm (LAI)
Number of subjects: 215
Study 39576977 — intervention group
Group type: EXPERIMENTAL
Intervention: User experience with LAI algorithm
Number of subjects: 215
Study 39576986 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective FES (Fesia Grasp)
Number of subjects: 80
Study 39576986 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional FES (Globus Elite)
Number of subjects: 80
Study 39576986 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Rehab Hands (Leap Motion sensor)
Number of subjects: 80
Study 39576986 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 80
Study 39576989 — intervention group
Group type: COMPARATOR
Intervention: Same-day surgery
Number of subjects: 439
Study 39576989 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged surgery
Number of subjects: 439
Study 39577033 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment
Number of subjects: 98
Study 39577128 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine visits with a psychologist conducting cognitive and mental health screenings, providing tailored brief psychotherapy and education.
Number of subjects: 17
Study 39577214 — intervention group
Group type: EXPERIMENTAL
Intervention: IV calcium chloride 90 mg (C90D)
Number of subjects: 217
Study 39577214 — intervention group
Group type: EXPERIMENTAL
Intervention: IV calcium chloride 180 mg (C180D)
Number of subjects: 217
Study 39577214 — intervention group
Group type: COMPARATOR
Intervention: IV NaCl 0.9% placebo (PD)
Number of subjects: 217
Study 39577214 — intervention group
Group type: EXPERIMENTAL
Intervention: IV calcium pretreatment (both doses)
Number of subjects: 217
Study 39577326 — intervention group
Group type: EXPERIMENTAL
Intervention: Khanya (peer-delivered behavioral intervention)
Number of subjects: 61
Study 39577326 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 61
Study 39577511 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived cell-free DNA (dd-cfDNA) levels before each EMB
Number of subjects: 206
Study 39577511 — intervention group
Group type: EXPERIMENTAL
Intervention: dd-cfDNA threshold of 0.10%
Number of subjects: 206
Study 39577511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dd-cfDNA and NTproBNP
Number of subjects: 206
Study 39577511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off point of 0.10% for dd-cfDNA and 1,000 UI/ml for NTproBNP
Number of subjects: 206
Study 39577691 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (ω3) and vitamin D (VitD) supplementation
Number of subjects: 88
Study 39577691 — intervention group
Group type: EXPERIMENTAL
Intervention: ω3+VitD group
Number of subjects: 88
Study 39577691 — intervention group
Group type: COMPARATOR
Intervention: ω3 group
Number of subjects: 88
Study 39577691 — intervention group
Group type: COMPARATOR
Intervention: VitD group
Number of subjects: 88
Study 39577708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (300,000 IU bolus followed by 1400 IU daily for 150 days)
Number of subjects: 307
Study 39577708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 39577708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 307